Welcome to our dedicated page for Universe Pharmaceuticals SEC filings (Ticker: UPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings and related disclosures for Universe Pharmaceuticals Inc. (UPC), a pharmaceutical producer and distributor in China focused on traditional Chinese medicine derivatives and third-party healthcare products. The company files reports as a foreign private issuer, and these documents offer detailed insight into its operations, financial condition, and corporate actions.
Key filings for Universe Pharmaceuticals include annual reports on Form 20-F, which present audited financial statements, risk factors, business descriptions, and information on traditional Chinese medicine derivatives (TCMD) products and third-party products. Interim financial information and significant corporate events are furnished on Form 6-K, such as financial highlights for the six months ended March 31, 2025, including revenue breakdowns between TCMD and third-party products, gross margin data, operating expenses, and net income or loss.
Universe Pharmaceuticals also uses Form 6-K to report corporate governance and capital structure matters. Examples include notices and proxy statements for annual general meetings of shareholders, results of shareholder votes, and details of capital reorganizations. One 6-K describes a capital reorganization involving a reduction in par value of issued ordinary shares, subdivision and alteration of authorized share capital, and the creation of new share classes with specified voting rights and conversion features, along with the redesignation of existing issued shares into those new classes.
Filings further document equity financing activities, such as registered direct offerings made under an effective shelf registration statement on Form F-3, as well as information about share consolidations (reverse share splits) and changes in authorized share capital. Listing-related developments, including Nasdaq notifications about minimum bid price, market value of publicly held shares, and delayed Form 20-F filings, may appear in 6-K reports as well.
On this page, AI-powered tools can help summarize lengthy filings, highlight key figures and trends, and point out important sections on topics such as revenue composition, operating performance, capital structure, and shareholder approvals. Users can review Forms 20-F and 6-K, along with other available documents, to understand Universe Pharmaceuticals’ regulatory disclosures and historical reporting.
Universe Pharmaceuticals Inc. reported the results of shareholder votes on corporate proposals. Five directors — Gang Lai, Lin Yang, Jiawen Pang, Ding Zheng and Yongping Yu — were re-elected, each receiving strong majority support, with two directors above 94.2% and the others ranging around 89.6%-89.9%. A special resolution to adopt an amended and restated memorandum and articles of association (the A&R M&A) following a proposed Capital Reorganisation received 74.74% support. An ordinary resolution to adjourn the meeting if needed received 77.79% support. The report lists vote percentages for each proposal, showing broadly high director support and a lower but positive vote for the A&R M&A.
Universe Pharmaceuticals INC reported that its 2025 annual general meeting of shareholders, originally convened on August 26, 2025, could not proceed because there were not enough shares represented to meet the required quorum. As a result, the meeting was formally adjourned to September 2, 2025 at 10:00 a.m. Beijing time.
The rescheduled meeting will take place at the company’s principal office at 265 Jingjiu Avenue in the Jinggangshan Economic and Technological Development Zone in Ji’an City, Jiangxi, China. The notice confirms that the company’s chief executive officer, Gang Lai, authorized this report.